Silexion Therapeutics Corp Ordinary Shares
SLXN XNASAbout Silexion Therapeutics Corp Ordinary Shares
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $32.0K | $-2,733,000 | $0.85 |
| Q3 2025 | $39.0K | $-3,262,000 | $2.88 |
| Q2 2025 | $44.0K | $-2,503,000 | $4.32 |
| Q1 2025 | $2.0K | $-1,735,000 | $0.26 |
TickerDaily Coverage
Get SLXN Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Silexion Therapeutics Corp Ordinary Shares.